STOCK TITAN

Rafael Holdings - RFL STOCK NEWS

Welcome to our dedicated page for Rafael Holdings news (Ticker: RFL), a resource for investors and traders seeking the latest updates and insights on Rafael Holdings stock.

Rafael Holdings (RFL) is a diversified holding company focused on clinical stage therapeutics, infusion technology, and strategic real estate. This page serves as your centralized source for official news, press releases, and updates across all business segments.

Access timely announcements on RFL's clinical development programs, mergers, and portfolio expansions. Investors will find critical updates on healthcare investments, infusion technology advancements, and real estate acquisitions. Content includes earnings reports, partnership agreements, and regulatory milestones.

Bookmark this page for direct access to RFL's verified corporate communications. Check regularly for insights into the company's progress in addressing high unmet medical needs and its balanced investment strategy across high-growth and stable sectors.

Rhea-AI Summary

LipoMedix announced that its lead compound, Promitil®, will be manufactured in the U.S. by ForDoz Pharma. Promitil® utilizes a pegylated liposomal delivery system for targeted cancer treatment, encapsulating a new chemical entity, Mitomycin-c lipidic prodrug (MLP), which has shown efficacy against various cancer types in studies. LipoMedix aims for Phase II clinical studies with the drug, expecting improved treatment options for patients. The partnership with ForDoz is intended to overcome manufacturing challenges in nanotechnology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
-
Rhea-AI Summary

Rafael Pharmaceuticals will present at the B. Riley Securities Virtual Oncology Investor Conference on January 20, 2021, outlining its progress in cancer metabolism therapeutics. CEO Sanjeev Luther and Co-CMO Tim Pardee will discuss clinical trial launches and FDA Fast Track designations. Specific achievements include FDA approval for pivotal Phase 3 trials in pancreatic cancer and acute myeloid leukemia using their lead compound CPI-613® (devimistat), which enhances cancer cell sensitivity to treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
conferences
-
Rhea-AI Summary

Rafael Pharmaceuticals announced that CEO Sanjeev Luther will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021. The presentation will cover significant milestones from 2020, including two FDA Fast Track designations for CPI-613 (devimistat), targeting metastatic pancreatic cancer and acute myeloid leukemia. Luther aims to highlight achievements and discuss future directions for tackling hard-to-treat cancers. The event will be accessible via webcast, with replays available on their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
conferences
Rhea-AI Summary

Rafael Holdings, Inc. (NYSE: RFL) announced a licensing agreement with Princeton University for exclusive rights to the SHMT inhibitor program, a part of their cancer drug development initiative through the Barer Institute. The SHMT inhibitors target metabolic pathways critical in various cancers, positioning the company for potential commercial drug development. Professor Joshua Rabinowitz expressed enthusiasm for collaborating with the Barer Institute in turning research findings into effective therapies, underscoring the importance of SHMT inhibitors in advancing cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
none
-
Rhea-AI Summary

Rafael Holdings (NYSE: RFL) reported Q1 FY 2021 revenue of $1.1 million, down from $1.2 million year-over-year. The company recorded a loss per share of $0.09, improving from $0.10 in Q1 FY 2020. The decline in revenue was partially offset by gains from commercial real estate sales. The company acquired a 33.33% interest in Altira, enhancing its royalty rights. Notably, CPI-613® received Fast Track designation from the FDA for treating metastatic pancreatic cancer and acute myeloid leukemia. Total cash and cash equivalents stood at $7.2 million as of October 31, 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.51%
Tags
-
Rhea-AI Summary

Rafael Pharmaceuticals announced that the FDA granted Fast Track designation for its lead compound, CPI-613® (devimistat), for treating acute myeloid leukemia (AML). This designation aims to expedite development and review processes due to the urgent need for new AML therapies. Rafael's President, Sanjeev Luther, emphasized the significance of this achievement amid COVID-19 challenges. The company had previously received Fast Track designation for devimistat in treating metastatic pancreatic cancer and achieved other regulatory milestones throughout the year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.93%
Tags
none
Rhea-AI Summary

Rafael Pharmaceuticals announced that the FDA has granted Fast Track designation to its lead compound, CPI-613® (devimistat), for treating acute myeloid leukemia (AML). This designation reflects the urgent need for new treatments for this aggressive disease. The company previously received Fast Track designation for devimistat in treating metastatic pancreatic cancer and has achieved several milestones, including Orphan Drug Designation for soft tissue sarcoma. The compound targets cancer cell metabolism, aiming to improve the effectiveness of chemotherapy while reducing side effects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.93%
Tags
none
-
Rhea-AI Summary

Rafael Pharmaceuticals has announced the initiation of a Phase 2 clinical trial for CPI-613® (devimistat) combined with hydroxychloroquine, targeting clear cell sarcoma. This collaboration involves Sara’s Cure and SARC, focusing on a rare cancer that predominantly affects young adults. The trial, part of Rafael's mission to develop treatments for hard-to-treat cancers, will take place at several U.S. sites, including Cleveland Clinic and University of Michigan. CPI-613® aims to enhance chemotherapy effectiveness while reducing side effects, having already received FDA orphan drug designation for multiple cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
-
Rhea-AI Summary

Rafael Pharmaceuticals has announced the initiation of a Phase 2 clinical trial for CPI-613® (devimistat) in combination with hydroxychloroquine to treat clear cell sarcoma. This rare cancer primarily affects young adults and has limited treatment options. Collaborating with Sara's Cure and SARC, the trial will enroll patients at several U.S. sites, including Cleveland Clinic and Indiana University. Devimistat targets cancer cell metabolism, enhancing the efficacy of chemotherapy while reducing side effects. The trial aims to provide hope for patients with this challenging disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
Rhea-AI Summary

Rafael Pharmaceuticals announced that the U.S. FDA has granted Fast Track designation for its lead compound, CPI-613® (devimistat), for treating metastatic pancreatic cancer. This designation highlights the urgent need for new treatment options for this aggressive cancer. Rafael also achieved target enrollment of 500 patients for its Phase 3 trial ahead of schedule. Additionally, devimistat has received Orphan Drug Designation for soft tissue sarcoma. The drug aims to enhance the effectiveness of chemotherapy while minimizing side effects, representing a significant advance in cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.47%
Tags
none
Rafael Holdings

NYSE:RFL

RFL Rankings

RFL Stock Data

53.84M
26.09M
20.86%
9.93%
0.39%
Real Estate Services
Pharmaceutical Preparations
Link
United States
NEWARK